Zacks.com submits:

Recently, Bristol-Myers Squibb Co. (BMY) announced that the advisory committee of the U.S. Food and Drug Administration (FDA) recommended approval for belatacept, the company’s candidate for treating patients undergoing kidney transplants.

The panel voted in favor of approving the drug despite mixed results compared to older therapies from Abbott Laboratories (ABT) and Novartis (NVS). The favorable recommendation was made primarily to provide physicians and patients with more treatment choices.

Complete Story »

Further information:

Article source

Related posts:

1. Bristol-Myers Squibb Gets an FDA Boost
2. Bristol-Myers Squibb: Looks Like a Good Value
3. FDA panel backs Bristol transplant drug
4. Why I Sold Walgreen and Bought Abbott
5. Abbott’s Estimates on the Rise